British Journal of Haematology
Издатель: Wiley · ISSN 00071048 · 80 статей
- Response to Vincenzi et al. on: ‘Real‐world treatment burden of BV‐based frontline regimens in young adults and adults with advanced‐stage classical Hodgkin lymphoma’
- CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives
- Nodular immunoglobulin‐associated pulmonary amyloidosis with extensive osseous metaplasia
- Even a worm may turn: Opportunistic strongyloides hyperinfection
- VEXAS syndrome with UBA1 p.Ser56Phe in a 46,XX woman
- Long‐read nanopore sequencing: A rapid and highly accurate approach for IGHV gene analysis in chronic lymphocytic leukaemia
- An unintended consequence of a FLT3 inhibitor
- Response to ‘Sustained MRD negativity or guaranteed survival time in multiple myeloma?’
- Interpreting thrombin and reptilase times: Beyond heparin contamination
- Long‐term relapse dynamics and relative survival after autologous haematopoietic stem cell transplantation for mantle cell lymphoma: 25‐year follow‐up of the Nordic MCL2 and MCL3 trials
- Real‐world treatment burden of brentuximab vedotin‐based front‐line regimens in young adults and adults with advanced‐stage classical Hodgkin lymphoma
- Haematological malignancies in paediatric and adolescents or young adults patients with Li‐Fraumeni syndrome: Retrospective multi‐institutional case series
- Estimated pulse wave velocity in ET and PV: A biologically plausible risk marker awaiting prospective validation
-
Complex karyotype and non‐BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia
Summary We retrospectively analysed 646 chronic lymphocytic leukaemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana‐Farber Cancer Institute from 2014 to 2023. Among them, 122 underwent next‐generation...
-
Risk factors for antepartum venous thromboembolism in pregnant people with sickle cell disease
Summary Sickle cell disease (SCD) is a thrombophilia exacerbated by pregnancy. However, there is not strong evidence for thromboprophylaxis, perhaps because most data addressing pregnancy‐related thrombosis in SCD is limited by...
- Practical Transfusion Medicine7th Edition Edited by Michael F. Murphy, Nancy M. Dunbar and Erica M. Wood, Wiley. 2026. ISBN‐10: 1394291965
-
Spatial and transcriptomic analyses reveal the adverse prognostic impact of regulatory T cells in follicular lymphoma treated with rituximab–lenalidomide
Summary The prognostic impact of the tumour microenvironment in follicular lymphoma (FL) remains controversial. To adress this, we analysed FL samples from patients enrolled in the rituximab lenalidomide versus any chemotherapy...
-
A real‐time text‐based assessment tool for monitoring symptoms and quality of life for multiple myeloma patients: A feasibility study
Summary Patient‐reported outcome (PRO) and quality of life (QoL) assessments for multiple myeloma (MM) patients are traditionally collected at infrequent intervals using burdensome instruments, resulting in limited clinical visibility...
-
CD20 antigen loss post‐venetoclax/anti‐CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment...
-
Caregiver support in patients with plasma cell dyscrasias: A novel single‐item pilot measure of caregiver availability: Results from a survey of >1000 patients
Summary Treatment for plasma cell dyscrasias imposes burdens on patients and caregivers, particularly for cellular therapies. Traditional social determinants of health may not capture caregiver availability. We conducted a...
- Response to: Comment on ‘Altered cytoskeletal integrity underlies impaired platelet shape change and defective thrombus formation in ETV6‐related thrombocytopenia’
- Comment on ‘Altered cytoskeletal integrity underlies impaired platelet shape change and defective thrombus formation in ETV6‐related thrombocytopenia’
-
Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study
Summary Rosai–Dorfman disease (RDD) is a rare histiocytic neoplasm with diverse clinical behaviour and immune abnormalities with unknown clinical significance. We performed a retrospective cohort study of 162 patients with RDD from 2003...
-
Indole‐3‐lactic acid ameliorates thrombocytopenia in primary immune thrombocytopenia by modulating the differentiation of Th17 and Tregs
Summary Although some patients with primary immune thrombocytopenia (ITP) benefit from current treatments, there are still some refractory patients. Our previous research showed that the imbalance of the intestinal microbiota is...
-
NPM1‐mutated AML: One entity, multiple layers of heterogeneity
Nucleophosmin 1 ( NPM1 ) mutations are found in around one third of all acute myeloid leukaemias (AMLs). However, little is known about the clinical role of the rare, non‐A NPM1 variants. Sangiorgio et al. showed that rare variants...
- Rare variants of NPM1 mutations share a similar molecular background to the common NPM1 type A variant and are associated with similar survival in adults with acute myeloid leukaemia
-
Orelabrutinib plus R‐CHOP in patients with newly diagnosed non‐GCB double‐expressor DLBCL: A single‐arm, phase II study
Summary Double‐expressor diffuse large B‐cell lymphoma (DE‐DLBCL) patients, defined by co‐expression of MYC proto‐oncogene protein (≥40%) and B‐cell lymphoma 2 protein (≥50%), typically have poor outcomes with the traditional first‐line...
- Response to venetoclax‐containing regimens in patients with relapsed/refractory (R/R) T‐cell acute lymphoblastic leukaemia (T‐ALL) and lymphoblastic lymphoma (T‐LBL)
- Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities
- A pro‐inflammatory cytokine signature characterises thrombotic antiphospholipid syndrome despite stable anticoagulation